# US 2019/0314526 A1 · Aav virions with decreased immunoreactivity and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314526 A1
- Document ID: US20190314526A1
- Status: Published application
- Kind: A1
- Application number: 16/261,424
- Filed: 2019-01-29
- Published: 2019-10-17
- Earliest claimed: 2003-06-19
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Alejandra E. ARBETMAN; Peter C. COLOSI; Michael A. LOCHRIE; Richard T. SUROSKY
- Web page: https://patentgrep.com/patent/US20190314526A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/04: for myasthenia gravis
- A61P 25/16: Anti-Parkinson drugs
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- C12N 2750/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14162: by genetic engineering
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/85: mammalian
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim at position 2

44: A mutated adeno-associated virus (AAV) capsid protein comprising a substitution of one or more of the amino acids occurring at a position corresponding to a position of the full-length AAV-2 VP2 capsid, wherein the one or more amino acids are selected from the group consisting of amino acid:
124 substituted with a threonine;
126 substituted with an alanine;
127 substituted with an alanine or a leucine;
128 substituted with an alanine or an aspartic acid;
130 substituted with a threonine or an alanine;
131 substituted with a glutamine or an alanine;
132 substituted with a glutamic acid, an alanine, or an asparagine;
133 substituted with an alanine;
134 substituted with a glutamine, a phenylalanine, or an alanine;
188 substituted with an alanine;
190 substituted with an alanine;
191 substituted with a serine;
193 substituted with an alanine;
245 substituted with an alanine;
246 substituted with an alanine;
247 substituted with an alanine;
248 substituted with an alanine;
315 substituted with an alanine;
317 substituted with an alanine;
318 substituted with an alanine;
320 substituted with an alanine;
322 substituted with an alanine;
329 substituted with an arginine;
331 substituted with an alanine;
332 substituted with an alanine;
334 substituted with an alanine;
335 substituted with an alanine;
347 substituted with a cysteine;
350 substituted with a lysine;
354 substituted with an alanine;
355 substituted with a threonine or an alanine;
356 substituted with an arginine;
357 substituted with a glutamic acid, a glutamine, an alanine, or an asparagine;
358 substituted with a lysine;
359 substituted with an alanine;
360 substituted with a histidine, a lysine, or an alanine;
361 substituted with an alanine;
362 substituted with an alanine;
365 substituted with a phenylalanine or an alanine;
366 substituted with a serine or an alanine;
372 substituted with a glutamine, a lysine, a phenylalanine, or an asparagine;
375 substituted with a proline or an alanine;
377 substituted with an alanine;
390 substituted with an alanine;
391 substituted with an alanine;
392 substituted with a glutamic acid, a valine, an alanine, an asparagine, or an isoleucine;
393 substituted with a glutamine, a lysine, an alanine, or an aspartic acid;
394 substituted with a lysine or an alanine;
395 substituted with an alanine;
396 substituted with an alanine;
407 substituted with an alanine;
411 substituted with a lysine or an alanine;
413 substituted with a lysine or an alanine;
418 substituted with an alanine;
419 substituted with an alanine;
437 substituted with an alanine;
438 substituted with an alanine;
448 substituted with a lysine or an alanine;
449 substituted with a lysine or an alanine;
450 substituted with a lysine or an alanine;
451 substituted with an alanine or lysine;
452 substituted with an alanine;
494 substituted with a proline;
568 substituted with a lysine or an alanine;
569 substituted with an alanine;
571 substituted with a lysine or an alanine; and
592 substituted with a lysine.

### Claim at position 3 (depends on 44)

45: The mutated AAV capsid protein of claim 44, wherein the one or more amino acids are selected from the group consisting of amino acid:
126 substituted with an alanine and 127 substituted with a leucine;
130 substituted with an alanine and 131 substituted with an alanine;
334 substituted with an alanine and 360 substituted with a lysine;
334 substituted with an alanine and 449 substituted with an alanine;
334 substituted with an alanine and 450 substituted with an alanine;
334 substituted with an alanine and 568 substituted with an alanine;
334 substituted with an alanine, 360 substituted with a lysine, 394 substituted with an alanine, 411 substituted with an alanine, 413 substituted with an alanine, and 449 substituted with an alanine;
334 substituted with an alanine, 360 substituted with a lysine, 394 substituted with an alanine, and 450 substituted with an alanine;
334 substituted with an alanine, 360 substituted with a lysine, 449 substituted with a lysine, and 568 substituted with a lysine;
334 substituted with an alanine, 360 substituted with a lysine, and 394 substituted with an alanine;
334 substituted with an alanine, 360 substituted with a lysine, and 449 substituted with a lysine;
334 substituted with an alanine, 360 substituted with a lysine, and 450 substituted with an alanine;
334 substituted with an alanine, 449 substituted with a lysine, and 568 substituted with a lysine;
334 substituted with an alanine, 449 substituted with an alanine, and 568 substituted with an alanine;
347 substituted with a cysteine, 449 substituted with an alanine, and 450 substituted with an alanine;
360 substituted with a histidine and 361 substituted with an alanine;
360 substituted with a lysine and 450 substituted with an alanine;
361 substituted with an alanine and 358 substituted with a lysine;
361 substituted with an alanine and 494 substituted with a proline;
361 substituted with an alanine and 592 substituted with a lysine;
411 substituted with an alanine and 413 substituted with an alanine;
411 substituted with an alanine, 413 substituted with an alanine, 449 substituted with an alanine, and 450 substituted with an alanine;
411 substituted with an alanine, 413 substituted with an alanine, 449 substituted with an alanine, 450 substituted with an alanine, 568 substituted with an alanine, and 571 substituted with an alanine;
449 substituted with a lysine and 568 substituted with a lysine;
449 substituted with an alanine and 450 substituted with an alanine;
450 substituted with an alanine, 568 substituted with an alanine, and 571 substituted with an alanine; and
568 substituted with an alanine and 571 substituted with an alanine.

### Claim at position 4 (depends on 44)

46: A polynucleotide encoding the mutated protein of claim 44.

### Claim at position 5 (depends on 45)

47: A polynucleotide encoding the mutated protein of claim 45.

### Claim at position 6 (depends on 44)

48: A recombinant AAV virion comprising the mutated protein of claim 44.

### Claim at position 7 (depends on 45)

49: A recombinant AAV virion comprising the mutated protein of claim 45.

### Claim at position 8 (depends on 48)

50: A method of delivering a recombinant AAV virion to a cell or tissue of a vertebrate subject, said method comprising:
(a) providing a recombinant AAV virion according to claim 48;
(b) delivering said recombinant AAV virion to said cell or tissue.

### Claim at position 9 (depends on 49)

51: A method of delivering a recombinant AAV virion to a cell or tissue of a vertebrate subject, said method comprising:
(a) providing a recombinant AAV virion according to claim 49;
(b) delivering said recombinant AAV virion to said cell or tissue.
